Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELITE: Tobramycin Regimens for Early P. aeruginosa in Cystic Fibrosis
NCT00391976Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2003
- Primary completion
- Jan 2008
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of tobramycin in cystic fibrosis (CF) (2 arms), sponsored by Novartis. Primary endpoint: Time to Recurrence of Pseudomonas Aeruginosa (Any Genotype) in Sputum or Deep Throat Cough Swab at Month 27. Started Nov 2003; status: completed.
02
Drugs
tobramycin
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT00391976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00391976.